Prostate cancer - InDepth

An in-depth report on the causes, diagnosis, treatment, and prevention of prostate cancer.

I Would Like to Learn About:

Related Reports

Benign prostatic h...

References

Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016;387(10013):70-82. PMID: 26074382 pubmed.ncbi.nlm.nih.gov/26074382/.

Barocas DA, Mallin K, Graves AJ, et al. Effect of the USPSTF Grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol. 2015;194(6):1587-1593. PMID: 26087383 pubmed.ncbi.nlm.nih.gov/26087383/.

Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709-717. PMID: 23689764 pubmed.ncbi.nlm.nih.gov/23689764/.

D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291-1293. PMID: 26393854 pubmed.ncbi.nlm.nih.gov/26393854/.

Eggener S. Hormonal therapy for prostate cancer. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 161.

Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914-1931. PMID: 29801018 pubmed.ncbi.nlm.nih.gov/29801018/.

Freedland SJ, Rumble RB, Finelli A, et al. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014;32(34):3892-3898. PMID: 25366677 pubmed.ncbi.nlm.nih.gov/25366677/.

Klotz L. Active surveillance of prostate cancer. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 154.

Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-2542. PMID: 28655021 pubmed.ncbi.nlm.nih.gov/28655021/.

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021;205(1):14-21. PMID: 32960679 pubmed.ncbi.nlm.nih.gov/32960679/.

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021;205(1):22-29. PMID: 32960678 pubmed.ncbi.nlm.nih.gov/32960678/.

PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Prostate cancer, nutrition, and dietary supplements (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2021 Mar 22. PMID: 26389500 pubmed.ncbi.nlm.nih.gov/26389500/.

PDQ Adult Treatment Editorial Board. Prostate cancer treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2021 Feb 12. PMID: 26389471 pubmed.ncbi.nlm.nih.gov/26389471/.

PDQ Screening and Prevention Editorial Board. Prostate Cancer Screening (PDQ®): Health Professional Version. 2021 Mar 18. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from: www.ncbi.nlm.nih.gov/books/NBK65945/.

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761-769. PMID: 23567643 pubmed.ncbi.nlm.nih.gov/23567643/.

Resnick MJ, Lacchetti C, Penson DF; American Society of Clinical Oncology. Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsement. J Oncol Pract. 2015;11(3):e445-e449. PMID: 25829527 pubmed.ncbi.nlm.nih.gov/25829527/.

Salami SS, Palapattu GS, Partin AW, Morgan TM. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 149.

Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645-657. PMID: 29412780 pubmed.ncbi.nlm.nih.gov/29412780/.

Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134-143. PMID: 33545689 pubmed.ncbi.nlm.nih.gov/33545689/.

Stephenson AJ, Abouassaly R, Klein EA. Epidemiology, etiology, and prevention of prostate cancer. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 148.

Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479-499. PMID: 30691365 pubmed.ncbi.nlm.nih.gov/30691365/.

US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. PMID: 29801017 pubmed.ncbi.nlm.nih.gov/29801017/.

Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39(11):1274-1305. PMID: 33497248 pubmed.ncbi.nlm.nih.gov/33497248/.

BACK TO TOP

Review Date: 5/29/2021  

Reviewed By: Kelly L. Stratton, MD, FACS, Associate Professor, Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complied with the HONcode standard for trustworthy health information from 1995 to 2022, after which HON (Health On the Net, a not-for-profit organization that promoted transparent and reliable health information online) was discontinued.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.